Method of enhancing hair growth

Details Method of enhancing hair growth Method of enhancing hair growth

2007-11-21

2011-10-18

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Live hair or scalp treating compositions

Reexamination Certificate

active

08038988

ABSTRACT:
Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula Iwherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1and R2are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

REFERENCES:
patent: 3382247 (1968-05-01), Anthony
patent: 3644363 (1972-02-01), Kim
patent: 4128577 (1978-12-01), Nelson
patent: 4139619 (1979-02-01), Chidsey
patent: 4311707 (1982-01-01), Birnbaum et al.
patent: 4543353 (1985-09-01), Faustini
patent: 4596812 (1986-06-01), Chidsey
patent: 4599353 (1986-07-01), Bito
patent: 4812457 (1989-03-01), Narumiya
patent: 4883819 (1989-11-01), Bito
patent: 4889845 (1989-12-01), Ritter
patent: 4952581 (1990-08-01), Bito
patent: 4968812 (1990-11-01), Wang
patent: 5001153 (1991-03-01), Ueno
patent: 5194429 (1993-03-01), Ueno
patent: 5280018 (1994-01-01), Ritter
patent: 5288754 (1994-02-01), Woodward et al.
patent: 5296504 (1994-03-01), Stjernschantz
patent: 5321128 (1994-06-01), Stjernschantz
patent: 5352708 (1994-10-01), Woodward
patent: 5422368 (1995-06-01), Stjernschantz
patent: 5422369 (1995-06-01), Stjernschantz
patent: 5480900 (1996-01-01), DeSantis
patent: 5508303 (1996-04-01), Isogaya
patent: 5510383 (1996-04-01), Bishop
patent: 5578618 (1996-11-01), Stjernschantz
patent: 5578643 (1996-11-01), Hanson
patent: 5607978 (1997-03-01), Woodward
patent: 5688819 (1997-11-01), Woodward
patent: 5698733 (1997-12-01), Hellberg
patent: 5773472 (1998-06-01), Stjernschantz
patent: 6025392 (2000-02-01), Selliah
patent: 6124344 (2000-09-01), Burk
patent: 6160129 (2000-12-01), Burk
patent: 6232344 (2001-05-01), Feng
patent: 6262105 (2001-07-01), Johnstone
patent: 6403649 (2002-06-01), Woodward
patent: 7288029 (2007-10-01), Lyon
patent: 7351404 (2008-04-01), Woodward
patent: 2002/0044953 (2002-04-01), Michelet et al.
patent: 2002/0172693 (2002-11-01), DeLong et al.
patent: 2003/0083381 (2003-05-01), Kumagai et al.
patent: 2003/0147823 (2003-08-01), Woodward
patent: 2003/0199590 (2003-10-01), Cagle
patent: 2005/0222232 (2005-10-01), DeLong et al.
patent: 2009/0018204 (2009-01-01), Brinkenhoff
patent: 1339132 (1997-07-01), None
patent: 0170258 (1986-02-01), None
patent: 0308135 (1989-03-01), None
patent: 0639563 (1995-02-01), None
patent: 2239458 (1973-07-01), None
patent: 49-69636 (1974-07-01), None
patent: 61-218510 (1986-09-01), None
patent: H09-295921 (1997-11-01), None
patent: 89/03384 (1989-04-01), None
patent: WO 95/11003 (1995-04-01), None
patent: WO 98/33497 (1998-08-01), None
patent: WO 01/74307 (2001-10-01), None
patent: WO 2009/011744 (2009-01-01), None
Jean-Paul Ortonne et al., “Hair Melanin's and Hair Color: Ultrastructural and Biochemical Aspects”, Journal of the Society for Investigative Dermatology, Inc., 1993, pp. 82S-89S.
Journal of the Americal of Pharmaceutical Association, New Drugs of 2001, “Agents for Glaucoma”, http://www.,edscape.com/viewarticle/436631—22, 2007, (4 pages).
Tania Zeigler, “Old Drug, New Use: New Research Shows Common Cholesterol-Lowering Drug Reduces Multiple Sclerosis Symptoms in Mice”, National Institute of Neurological Disorders and Stroke, 2003, (2 pages).
Meolineplus. Health Information “Bimatoprost (Ophtalmic)”,[Online] Jul. 24, 2001, XP002245126 Retrieved from the Internet: URL:www.nlm.nih.gov/medlineplus/druginfor/uspdi/500295; [retrieved on Jun. 23, 2003].
Preparation Of '404 Patent Documents for European Patent Office; Invalidity Contentions Pursuant to Patent Local Rule 3-3.
Preparation Of '404 Patent Documents for European Patent Office; Defendant ATHENA Cosmetics, Inc.; Supplemental Invalidity Contentions Pursuant to Patent Local Rule 3-3.
Preparation Of '404 Patent Documents for European Patent Office; Defendant Peter Thomas Roth Labs LLC and Peter Thomas Roth, Inc.'s Invalidity Contentions Pursuant to Patent Local Rule 3-3.
Preparation Of '404 Patent Documents for European Patent Office; Defendants Metrics LLC, Product Innovations LLC; Stella International LLC; and Nutra-Luxe, M.D. LLC's ; Local Patent Rule 3-3 Preliminary Invalidity Contentions.
Medical Officer's Review of NDA 21-275; Mar. 2, 2001.
Medical Officer's Review of NDA 21-275; 120-day safety Update Jan. 23, 2001.
Medical Officer's Review of NDA 21-275; Original Sep. 18, 2000.
U.S. Appl. No. 10/663,014, filed Sep. 15, 2003, Krauss.
Re. U.S. Appl. No. 90/009,430, filed Mar. 15, 2009, Woodward.
Re. U.S. Appl. No. 90/009,431, filed Mar. 10, 2009, Johnstone.
Alm, A. and Stjernschantz, J.: Effects on Intraocular Pressure and Side Effects of 0.005% Latanoprost Applied Once Daily, Evening or Morning, Ophthalmology, vol. 102, No. 12 at 1743-1752, 1995.
Bito, Laszlo: A New Approach to the Medical Management of Glaucoma, from the Bench to the Clinic, and Beyond. The Proctor Lecture, May 2001, vol. 42, No. 6.
Brandt, James D.: Comparison of Once- or Twice-Daily Bimatoprost with Twice-Daily Timolol in Patients with Elecated IOP, Ophthalmology, vol. 108, No. 6, Jun. 2001 at 1023-1031.
FDA Approves Two New intraocular Pressure Lowering Drugs for the Management of Glaucoma, FDA News, Mar. 16, 2001.
Fiscella, Richard G.: Peek into the Drug Pipeline, Review of Optometry Online, Jan. 15, 2001.
Geng, I.: Topical or Systemic 16,16 dm Prostaglandin E2 or WR-2721 Protects Mice From Alopecia After Fractioned Irradiation, Int. J. Radiation Oncology Biol. Phys., vol. 61, No. 4 at 533-537, 2005.
Hanson, W.R.; et al.: Subcutaneous or Topical Administration of 16,16 Dimethyl Prostaglandin E2 Protects From Radiation-Induced Alopecia in Mice, Int. J. Radiation Oncology Biol. Phys. 1992. vol. 23 at 333-337.
Jeff Gerth, et al., Drug Makers Reap Profits on Tax-Backed Research, New York Times, Apr. 23, 2000.
Lumigan 6-Month Phase 3 Data Presented at American Glaucoma Society Meeting. Mar. 2, 2001, Business Wire.
Medical Review, Application No. 21-275, Center for Drug Evaluation and Research, 2010.
Pfeiffer, N.: New Developments in Glaucoma Drug Therapy, Ophthalmologist (1992) 89: W1-W13.
Phase 3 Lumigan—AGN 192024- Data Presented At American Academy of Opthalmology, Business Wire, 2000.
Phase 3 Lumigan—AGN 192024—Data Presented At American Academy of Opthalmology, Allergan Press Release, 2000.
Roenigk: New Topical Agents for Hair Growth, Clinics in Dermatology, vol. 6, No. 4 at 119-121, 1988.
The Newsletter of Glaucoma Foundation, Fall 2000, vol. 11, No. 2.
Wand, Martin: Latanoprost and Hyperpigmentation of Eyelashes, Archives of Ophthalmology, vol. 115, pp. 1206-1208, 1997.
Watson, P. and Stjernschantz, J.: A Six-Month, Randomized, Double-masked Studying Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension, Ophthalmology, vol. 103 at p. 126-137, 1995.
Woodward, David: Replacement of Carboxylic Acid Group of Prostaglandin F2a with a Hydroxyl or Methoxy Substituent Provides Biologically Unique Compounds, British Journal of Pharmacology, vol. 130, No. 8, Aug. 2000 at 1933-1943.
U.S. Appl. No. 11/805,122, filed May 22, 2007, Woodward et al.
U.S. Appl. No. 11/943,714, filed Jan. 21, 2007, Woodward et al.
Preparation OF '404 Patent Documents for European Patent Office; Invalidity Contentions Pursuant to Patent Local Rule 3-3, 2008.
Preparation OF '404 Patent Documents for European Patent Office; Defendant Athena Cosmetics, Inc.; Supplemental Invalidity Contentions Pursuant to Patent Local Rule 3-3. 2008.
Preparation OF '404 Patent Documents for European Patent Office; Defendant Peter Thomas Roth Labs LLC and Peter Thomas Roth, Inc.'s Invalidity Contentions Pursuant to Patent Local Rule 3-3, 2008.
Preparation OF '404 Patent Documents for European Patent Office; Defendants Metrics LLC, Product Innovations LLC; Stella International LLC; and Nutra-Luke, M.D. LLC's Local Patent Rule 3-3 Preliminary Invalidity Contentions, 2008.
Declaration of Larry Wheeler, Ph.D.; Dec. 14, 2010

Affiliated with

Also associated with

Rating

Method of enhancing hair growth does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of enhancing hair growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing hair growth will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4292059